Skip to main content
Atrás
Watch Compare

Xilio Therapeutics, Inc.

Calidad de datos: 100%
XLO
Nasdaq Manufacturing Chemicals
$8.55
▼ $0.14 (-1.61%)
Cap. Mercado: 49.44 M
Precio
$8.55
Cap. Mercado
49.44 M
Rango del Día
$8.55 — $8.68
Rango de 52 Semanas
$6.47 — $16.52
Volumen
7,721
Apertura $8.68
Promedio 50D / 200D
$7.91
8.06% above
Promedio 50D / 200D
$9.57
10.65% below

Quick Summary

Puntos Clave

Negative free cash flow of -5.51 M
Capital efficient — spends only 1.18% of revenue on capex

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)589.88%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
N/A
ROIC-42.02%
Net Margin-80.05%
Op. Margin-95.92%

Seguridad

Debt / Equity
N/A
Current Ratio2.20
Interest CoverageN/A

Valoración

PE (TTM)
-1.41
Above sector avg (-1.98)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (44 pares)
Métrica Acción Mediana del Sector
P/E -1.4 -2.0
P/B — 5.1
ROE % — -51.0
Net Margin % -80.1 -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 589.88% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 43.77 M Net Income (TTM) -35.04 M
ROE N/A ROA -26.19%
Gross Margin N/A Operating Margin -95.92%
Net Margin -80.05% Free Cash Flow (TTM) -5.51 M
ROIC -42.02% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.20
Interest Coverage N/A Asset Turnover 0.33
Working Capital 67.69 M Tangible Book Value -8.10 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.41 Forward P/E N/A
P/B Ratio N/A P/S Ratio 1.13
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -11.14%
Market Cap 49.44 M Enterprise Value -54.32 M
Per Share
EPS (Diluted TTM) -4.19 Revenue / Share 7.57
FCF / Share -0.95 OCF / Share -0.86
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1.18% FCF Conversion 15.73%
SBC-Adj. FCF -11.09 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 43.77 M 6.34 M — — —
Net Income -35.04 M -58.24 M -76.40 M -88.22 M -75.80 M
EPS (Diluted) -4.19 -1.09 -2.78 -3.22 -13.52
Gross Profit — — — — —
Operating Income -41.98 M -60.58 M -79.13 M -89.15 M -75.04 M
EBITDA — — — — —
R&D Expenses 56.04 M 41.21 M 52.14 M 59.20 M 51.19 M
SG&A Expenses — — — — —
D&A 1.54 M 1.64 M 1.90 M 1.85 M 1.50 M
Interest Expense — — — — —
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 154.69 M 71.08 M 60.93 M 139.17 M 218.06 M
Total Liabilities 119.41 M 53.48 M 24.10 M 33.52 M 32.63 M
Shareholders' Equity 35.27 M 17.60 M 36.83 M 105.65 M 185.43 M
Total Debt — — — — —
Cash & Equivalents 137.53 M 55.29 M 44.70 M 120.39 M 198.05 M
Current Assets 145.03 M 60.23 M 48.13 M 124.50 M 202.52 M
Current Liabilities 56.27 M 27.26 M 15.96 M 21.12 M 12.78 M